A detailed history of Foresite Capital Management V, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Foresite Capital Management V, LLC holds 8,133,047 shares of LYEL stock, worth $5.69 Million. This represents 14.48% of its overall portfolio holdings.

Number of Shares
8,133,047
Holding current value
$5.69 Million
% of portfolio
14.48%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.59 - $1.48 $4.8 Million - $12 Million
8,133,047 New
8,133,047 $5.21 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $173M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Foresite Capital Management V, LLC Portfolio

Follow Foresite Capital Management V, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foresite Capital Management V, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Foresite Capital Management V, LLC with notifications on news.